Fusion Antibodies

Fusion Antibodies is a CMO that offers a range of services covering all stages of therapeutic and diagnostic antibody development from target discovery to delivery of lead optimized commercial candidates suitable for cGMP scale up.

Fusion provides contract services include...

- Antibody Humanization services

- Antibody Engineering Services

- Antibody sequencing Services

- Protein Expression & Purification Services

- Monoclonal Antibody services BLAST & Standard

- cGMP Services

Fusion Therapeutics (a division of Fusion Antibodies) is committed to developing therapeutic antibodies and recombinant proteins to disease specific markers. Fusion Therapeutics is primarily focused on the key areas of oncology and angiogenesis where immunotherapeutic intervention has a proven track record. The company’s genomic mining and proteomic discovery strategy has resulted in the development of a growing pipeline of candidate drugs. Fusion Antibodies have a number of exciting targets undergoing validation with two targets currently in preclinical trials.

Company Growth (employees)
Type
Private
HQ
Dunmurry, GB
Founded
2001
Size (employees)
15 (est)-6%
Fusion Antibodies was founded in 2001 and is headquartered in Dunmurry, GB

Fusion Antibodies Office Locations

Fusion Antibodies has an office in Dunmurry

Fusion Antibodies Data and Metrics

Summary Metrics

Founding Date

2001

Total Funding

$2.5 m

Latest funding size

$2.5 m

Time since last funding

almost 10 years

Investors

Fusion Antibodies's latest funding round in July 2007 was reported to be $2.5 m. In total, Fusion Antibodies has raised $2.5 m

Fusion Antibodies Financial Metrics

Fusion Antibodies's revenue was reported to be £723 k in FY, 2014 which is a 79% increase from the previous period.
Numbers are in £, GBP

Revenue (FY, 2014)

723 k

Revenue growth (FY, 2013 - FY, 2014), %

79%

Gross profit (FY, 2014)

357.7 k

Gross profit margin (FY, 2014), %

49%

Net income (FY, 2014)

(113.5 k)

Cash (31-Mar-2016)

413.9 k
Numbers are in £, GBPFY, 2013FY, 2014

Revenue

405 k723 k

Revenue growth, %

79%

Cost of goods sold

324.2 k365.3 k

Gross profit

80.8 k357.7 k

Gross profit Margin, %

20%49%

Operating expense total

554 k477.1 k

Pre tax profit

(120.5 k)

Net Income

(113.5 k)
Numbers are in £, GBPFY, 2014FY, 2015FY, 2016

Cash

139.1 k103.6 k413.9 k

Accounts Receivable

86.5 k205.3 k255.7 k

Current Assets

269.2 k309 k669.7 k

PP&E

44.7 k36.4 k50 k

Total Assets

313.9 k345.4 k719.6 k

Accounts Payable

258.8 k181.7 k391.4 k

Current Liabilities

297.6 k181.7 k391.4 k

Retained Earnings

(113.5 k)

Total Equity

(3.7 k)143.8 k308.2 k

Financial Leverage

-85.3 x2.4 x2.3 x
Numbers are in £, GBPFY, 2014

Income Taxes Paid

6.9 k
Y, 2016

Financial Leverage

2.3 x

Fusion Antibodies Online and Social Media Presence

Fusion Antibodies Company Life and Culture

You may also be interested in